Vaxart, Inc. BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart’s oral pill vaccine platform as a next-generation approach to...
Vaxcyte, Inc. — VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 — — Following VAX-31 Adult Phase 1/2 Study...